Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.
Sarafraz-Yazdi. Ehsan E; Bowne. Wilbur B WB; Adler. Victor V; Sookraj. Kelley A KA; Wu. Vernon V; Shteyler. Vadim V; Patel. Hunaiz H; Oxbury. William W; Brandt-Rauf. Paul P; Zenilman. Michael E ME; Michl. Josef J; Pincus. Matthew R MR
Key Findings
- PNC-27 binds to HDM-2 on the membranes of a wide range of cancer cells.
- Binding triggers membrane rupture (membranolysis) that kills the cancer cells.
- Normal, non‑cancerous cells lack surface HDM-2 and are not affected; adding HDM-2 to them makes them vulnerable.
Practical Outcomes
- At this stage the peptide is only a laboratory tool, not a usable supplement or drug. It points to HDM-2 as a promising target for future anti‑cancer therapies, so biohackers should watch for clinical developments but not attempt self‑administration.
Summary
Scientists discovered that a short protein called PNC-27 can kill cancer cells but leaves normal cells unharmed. It works by latching onto a protein called HDM-2 that sits on the surface of many cancer cells, then punching holes in the cell membrane. Normal cells don’t have HDM-2 on their surface, so they’re safe.
Abstract
The anticancer peptide PNC-27, which contains an HDM-2-binding domain corresponding to residues 12-26 of p53 and a transmembrane-penetrating domain, has been found to kill cancer cells (but not normal cells) by inducing membranolysis. We find that our previously determined 3D structure of the p53 residues of PNC-27 is directly superimposable on the structure for the same residues bound to HDM-2, suggesting that the peptide may target HDM-2 in the membranes of cancer cells. We now find significant levels of HDM-2 in the membranes of a variety of cancer cells but not in the membranes of several untransformed cell lines. In colocalization experiments, we find that PNC-27 binds to cell membrane-bound HDM-2. We further transfected a plasmid expressing full-length HDM-2 with a membrane-localization signal into untransformed MCF-10-2A cells not susceptible to PNC-27 and found that these cells expressing full-length HDM-2 on their cell surface became susceptible to PNC-27. We conclude that PNC-27 targets HDM-2 in the membranes of cancer cells, allowing it to induce membranolysis of these cells selectively.
Study Information
pubmed
2010
2010-01-11T00:00:00.000Z
10.1073/pnas.0909364107
31
27